Andrew Berens
Stock Analyst at Leerink Partners
(0)
# 4258
Out of 5,253 analysts
219
Total ratings
46.94%
Success rate
-6.92%
Average return
Main Sectors:
Top Industries:
| Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
OnKure Therapeutics | Initiates Coverage On: Outperform | 33 | 4.93 | 569.37% | 1 | Dec 5, 2024 | |
Zymeworks | Upgrades: Outperform | 10 25 | 14.46 | 72.89% | 10 | Nov 7, 2024 | |
Gilead Sciences | Upgrades: Outperform | 74 96 | 95.94 | 0.06% | 1 | Oct 21, 2024 | |
Agios Pharmaceutical... | Downgrades: Market Perform | 60 56 | 33.49 | 67.21% | 11 | Sep 27, 2024 | |
Viracta Therapeutics | Downgrades: Market Perform | 5 3 | 0.16 | 1775% | 5 | Aug 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 29 | 11.36 | 155.28% | 1 | Jul 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Market Perform | 50 97 | 114.02 | -14.93% | 24 | May 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Outperform | 69 110 | 83.62 | 31.55% | 1 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Outperform | 78 | 73.52 | 6.09% | 12 | Dec 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Market Perform | 78 58 | n/a | n/a | 7 | Nov 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Outperform | 5 8 | 0.59 | 1255.93% | 4 | May 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Market Perform | 13 10 | n/a | n/a | 2 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 35 48 | 40.2 | 19.4% | 5 | Apr 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Outperform | 30 | n/a | n/a | 11 | Feb 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Market Perform | 162 141 | n/a | n/a | 19 | Feb 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 236 300 | n/a | n/a | 11 | Jan 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 18 20 | 8.81 | 127.01% | 4 | Jan 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 37 28 | 19.53 | 43.37% | 3 | Dec 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 74 70 | 18 | 288.89% | 5 | Nov 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 78 79 | 69.66 | 13.41% | 12 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 42 27 | 2.31 | 1068.83% | 7 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Market Perform | n/a | n/a | n/a | 4 | Oct 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 40 30 | 2.09 | 1335.41% | 4 | Aug 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Market Perform | 69 | n/a | n/a | 4 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Market Perform | 101 76 | n/a | n/a | 6 | Jun 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 25 23 | n/a | n/a | 5 | May 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 36 25 | 10.35 | 141.55% | 3 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 9 11 | 3.28 | 235.37% | 2 | May 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 40 | 7.82 | 411.51% | 1 | Nov 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 28 | n/a | n/a | 1 | Nov 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 67 | 3.65 | 1735.62% | 1 | Oct 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Market Perform | 20 | 5.68 | 252.11% | 1 | Oct 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 25 | 3.06 | 716.99% | 1 | Sep 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Outperform | 12 16 | n/a | n/a | 5 | May 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Underperform | 4 3 | n/a | n/a | 6 | Nov 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reinstates: Overweight | 2000 | n/a | n/a | 2 | Sep 7, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 156 146 | n/a | n/a | 3 | Mar 1, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 102 18 | n/a | n/a | 2 | Sep 22, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Underweight | 75 50 | n/a | n/a | 5 | Sep 22, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 16 8 | 7.9 | 1.27% | 7 | Jul 14, 2017 |